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Abstract
Background: Asthma exacerbations remain a major unmet clinical need. The difficulty in obtaining airway tissue and
bronchoalveolar lavage samples during exacerbations has greatly hampered study of naturally occurring exacerbations. This
study was conducted to determine if mRNA profiling of peripheral blood mononuclear cells (PBMCs) could provide
information on the systemic molecular pathways involved during asthma exacerbations.
Methodology/Principal Findings: Over the course of one year, gene expression levels during stable asthma, exacerbation, and
twoweeks after an exacerbation were compared using oligonucleotide arrays. For each of 118 subjects who experienced at least
one asthma exacerbation, the gene expression patterns in a sample of peripheral blood mononuclear cells collected during an
exacerbation episode were compared to patterns observed in multiple samples from the same subject collected during
quiescent asthma. Analysis of covariance identified genes whose levels of expression changed during exacerbations and returned
to quiescent levels by two weeks. Heterogeneity among visits in expression profiles was examined using K-means clustering.
Three distinct exacerbation-associated gene expression signatures were identified. One signature indicated that, even among
patients without symptoms of respiratory infection, genes of innate immunity were activated. Antigen-independent T cell
activation mediated by IL15 was also indicated by this signature. A second signature revealed strong evidence of lymphocyte
activation through antigen receptors and subsequent downstream events of adaptive immunity. The number of genes identified
in the third signature was too few to draw conclusions on the mechanisms driving those exacerbations.
Conclusions/Significance: This study has shown that analysis of PBMCs reveals systemic changes accompanying asthma
exacerbation and has laid the foundation for future comparative studies using PBMCs.
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Introduction
While asthma is a chronic inflammatory disorder of the
conducting airways causing variable airflow obstruction, sudden
deterioration of asthma control in the form of exacerbations, even
in the presence of adequate controller therapy, creates a major
unmet clinical need. At worst, exacerbations can lead to death,
and at best to unscheduled healthcare interventions accounting for
most hospital admissions for asthma. Asthma exacerbations are
caused by a wide variety of different factors acting singly or
together including inadequate controller therapy, exposure to
environmental insults (especially allergens, infectious agents, air
pollutants, irritant chemicals, and certain drugs) as well as
endogenous factors such as changes in sex hormones and
psychological stress [1]. The frequency and severity of asthma
exacerbations can be reduced by adherence to asthma manage-
ment guidelines and adequate use of controller therapy. Indeed
the most recent guidelines (GINA, BTS and US) advocate control
of baseline asthma and prevention of exacerbations as the optimal
targets of therapy. While some causes of exacerbating asthma
(such as those resulting from inadequate baseline therapy, poor
compliance and allergen exposure) can be effectively modified by
increasing anti-inflammatory therapy, especially inhaled cortico-
steroids, others (such as those triggered by virus infection or air
pollution episodes) are much less responsive. Indeed, clinical trials
of doubling the dose of inhaled corticosteroids at the onset of a
naturally occurring exacerbation have shown no beneficial effect
[2,3], although higher doses and oral corticosteroids are more
effective [4]. Adequate doses of inhaled corticosteroids alone or in
combination with long-acting b2-adrenoceptor agonists, leukotri-
ene receptor antagonists and/or anti-IgE monoclonal antibody
result in reduced number and severity of exacerbations. These
effects of therapy are likely due to a combination of reduced
baseline airway inflammation, bronchodilatation and variable
suppression of the underlying cellular mechanisms that drive the
exacerbation itself [5]. However, even in the case of biologics that
target highly selected pathways such as monoclonal antibodies
against IgE (omalizumab) and/or IL5, their effectiveness will be
limited to exacerbation subtypes that utilize these inflammatory
pathways [6,7].
Although much is now known about the immunological,
inflammatory cells and mediators involved in different asthma
subtypes, it is surprising that almost nothing is known about the
mechanisms involved in exacerbations other than that they are
triggered by inadequate controller therapy, respiratory viral
infection and allergen exposure. A dominant eosinophil or mixed
eosinophil and neutrophil response in blood, sputum and
bronchoalveolar lavage and release of a range of inflammatory
mediators, cytokines and chemokines during exacerbations
strongly supports the existence of heterogeneous mechanisms
[8]. Difficulty in obtaining airway tissue and lavage samples during
naturally occurring exacerbations has greatly hampered the study
of their underlying mechanisms. However, in one bronchial biopsy
study of severe asthma exacerbations, there was a similar increase
in the number of mucosal eosinophils and neutrophils that was
accompanied by increased expression of mRNA for the chemo-
kines CXCL5 (epithelial cell-derived neutrophil-activating pep-
tide-78) and CXCL8 (IL8) and their receptors CXCR1 and
CXCR2, but the mechanisms involved are unknown [9].
Based on the paucity of mechanistic information on asthma
exacerbations, the aim of the current study was to determine if
mRNA profiling of peripheral blood mononuclear cells (PBMCs)
could provide new insights into the systemic molecular pathways
involved during naturally asthma exacerbations in patients with a
range of asthma severity. Some of the results of these studies have
been previously reported in the form of an abstract [10].
Materials and Methods
This was a prospective, multi-center non-interventional study
conducted in Australia, Iceland, Ireland, U.K., and USA, and
approved by the respective Institutional Review Boards or Ethics
Committees. The names of the institutional review boards that
approved this study are: Research Ethics Committee, Royal
Adelaide Hospital, Adelaide, Australia, The Sir Charles Gardiner
Hospital Human Research Ethics Committee, Nedlands, Austra-
lia, Sothern Health Human Research Ethics Committee, Monash
Medical Center, Clayton, Victoria, Australia, Human research
Ethics Committee, The Royal Melbourse Hospital, Parkville,
Australia, Western Institutional Review Board, Olympia, Wa-
hington, USA, Quorum Review Inc, Seattle, Washington, USA,
Sterling Institutional Review Board, Atlanta, Georgia, USA, Yale
University Human Investigation Committee, New Haven, Con-
necticut, USA, Institutional Review Board, Saint Barnabus Health
Care System, Newark, Newjersey, USA, Medical Ethics Commit-
tee, Northern Health Board, Dubline, Ireland, Southampton
&South West hants Local research Ethics Committee, South-
ampton, UK, Leicestershir, Northamptonshire and Rutland
Health Authority Committee on the Ethics of Clinical Research
Investigation, Leicerster, UK, National Bioethics Committee,
Reykjavik, Iceland. All subjects gave their written informed
consent, were aged $18 years and had a confirmed diagnosis of
mild persistent, moderate persistent, or severe persistent bronchial
asthma according to the 1997 Guidelines for the Diagnosis and
Management of Asthma [11] Subjects were stratified by disease
severity and had to have demonstrated an improvement in forced
expiratory volume in 1 second (FEV1) of $12% from the baseline
in response to an inhaled short-acting b2-adrenoceptor agonist
within 12 months of screening and/or a provocative concentration
of methacholine causing a 20% fall in FEV1 (PC20) of,8 mg/mL.
Exclusion criteria included an active infection, major intercurrent
illness, allergen immunotherapy, pregnancy or lactation. At
screening, baseline information collected included a detailed
medical and asthma history, medication use, physical examination
and spirometry. The pattern of asthma over the 12 month
observation period is supplied in Text S1.
Subjects attended the clinic every 3 months throughout the
course of the 12-month study with asthma assessments performed
at each visit. In addition, at the first sign of an exacerbation attack
subjects were asked to attend the assessment clinic as soon as
feasible, and again within two weeks of recovery from exacerba-
tion. At each visit, venous blood samples were collected. Thus
there were three types of blood samples collected: 1) Quiet - during
stable disease at approximately 3-month intervals, 2) Exacerbation -
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during a 14 day window during which subjects were experiencing
symptoms of exacerbation attack and 3) Follow-up - within a 14 day
window following cessation of the exacerbation attack. Exacerbation
samples were collected while the subjects were experiencing one or
more of the following symptoms – increases in wheezing, chest
tightness, and/or shortness of breath. There was no restriction on
medication use in the management of these patients either when
stable or during exacerbations.
Analytical Samples
PBMCs from asthma subjects were isolated from whole blood
samples (8 ml66 tubes) collected into cell purification (CPT) tubes
(Becton Dickinson, Franklin Lakes, NJ) according to the
manufacturer’s recommendations. All samples were shipped at
room temperature in a temperature controlled box overnight from
the clinical site, cell differential counts taken, PBMCs purified
according to CPT manufacturer instructions, (Table S1), and cell
pellets stored at 280uC pending RNA purification. RLT lysis
buffer (with 0.1% b-mercaptoethanol) was added to frozen pellets,
RNA isolated using RNeasy Mini Kit (Qiagen, Valencia, CA) and
DNase treated (Qiagen RNase-free DNase Kit). Eluted RNA was
quantified using a Spectramax96 well plate UV reader (Molecular
Devices, Sunnyvale, CA, USA) monitoring A260/280 OD values.
The quality of each RNA sample was assessed by the integrity of
the 28S and 18S peaks by capillary electrophoresis alongside an
RNA molecular weight ladder on the Agilent 2100 bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA). RNA was quantified
using Spectramax96 (Molecular Devices, Sunnyvale, CA).
Determining RNA Expression Level
Labelled targets for oligonucleotide arrays were prepared using
2 mg of total RNA according to the protocol provided by
Affymetrix (Santa Clara, CA). Biotinylated cRNA was hybridized
to the HG-U133A Affymetrix GeneChip ArrayH which interro-
gates 23,283 probe sets. Raw intensity values were processed using
Affymetrix MAS 5.0 software, which calculated signal expression
levels and present/absent calls for each probe set. More detailed
descriptions of sample preparation, mRNA expression measure-
ments using the Affymetrix U133A GeneChip and quality control
acceptance criteria for GeneChip data are given in the Table S2.
Gene expression data for all arrays run has been submitted to
NCBI GEO, accession number 19301. Expression levels of
polymorphic HLA DQA1 and HLADQB1, and a Y-chromosome
specific transcript, RPS4Y1 were checked for each sample from
each donor to ensure that each sample was associated with the
correct donor, i.e. erroneous sample switching had not occurred.
ANCOVA and K-Means Analyses
The multiple samples drawn from a given subject during
periods of quiet asthma served as the control comparators for
samples drawn from the same patient during exacerbations. This
repeated-measures study design provided the power to detect
changes associated with exacerbation across the large number of
subjects analyzed. There were at least 3 quiet samples for 85% of
the 118 subjects in the study. The percentage of subjects with 1, 2,
3, 4 or 5 quiet samples is shown in Figure S1. Levels and variability
of gene expression during quiet visits in each subject was calculated
using all quiet samples from the subject.
For each probe set, mean expression levels during quiet,
exacerbation, and follow-up visits were compared using repeated-
measures analysis of covariance (ANCOVA), (see Text S1 for
more detailed description). Heterogeneity of expression during
quiet states was factored into the ANCOVA, and only exacerba-
tion-associated differences that fell significantly outside the levels
observed during quiet periods were examined in further detail. In
these analyses, log2-transformed signal was the response variable,
and asthma severity, sex, age category, race, geographical location,
visit type, corticosteroid exposure, leukotriene receptor antagonist
use, RNA quality and monocyte to lymphocyte ratio were the
explanatory variables. To adjust for multiplicity of testing, false
discovery rates (FDRs) were calculated across all probe sets,
separately for each term in the ANCOVA model or pair-wise
contrast using SAS version 9.1 [12]. Additional information is
provided in Text S1.
An initial ANCOVA compared mean log2 expression levels
during exacerbations with levels during quiet visits. All genes with
mean differences between exacerbation and quiet visits that were
statistically significant at the 0.05 level (unadjusted p-value ,0.05)
were identified. Heterogeneity in the expression profiles of this set
of genes among samples was evaluated using K-means clustering
[13]. Specifically, the input to the K-means analysis was the
difference between the log2 expression level of each exacerbation visit
and the mean log2 expression level of quiet visits for the same
subject. The K-means clustering partitioned samples solely on the
basis of similarity in gene expression profile, i.e. in the absence of
additional sample-related information supplied by the investigator.
K-means clustering was executed using the R software package
(version 2.1.1; www.r-project.org). To estimate the number of
exacerbation sub-groups that were present within the dataset,
repeated K-means cluster analyses were run, setting K (the
number of subgroups) to each possible value between 2 and 8. For
each number of subgroups, we assessed the separability and
robustness of the resulting clusters. Higher separability and
robustness reproducibly revealed distinguishable subgroups of
exacerbation responses. Separability and robustness were mea-
sured using the silhouette statistic (SW) [14] and a simulation-
based robustness index (R) [15]. For the robustness index
calculation, Gaussian random noise with zero mean and realistic
amplitude (a standard deviation of 0.3) was computationally added
to the observed log-ratios to simulate biological replication. For
each of 100 realizations of the noisy data, K-means clustering was
executed as described above, and the co-clustering of all donor
pairs recorded. The resulting co-clustering matrix was then
divided by the number of realizations (100) to yield a symmetrical
matrix of cluster co-occurrence fractions for every sample-pair in
the dataset. Additional details describing the evidentiary support
for dividing the exacerbation samples into 3 subgroups are provided
in Text S1.
Based on the K-means assignments of exacerbation visits to three
subgroups, an ANCOVA was performed to compare log2 mean
expression for exacerbation visits within each subgroup with mean
expression during the quiet visits. The exacerbation versus quiet
comparison was calculated separately for each exacerbation-
associated gene. Since these ANCOVAs were performed using
exacerbation visits grouped on the basis of similarities in expression
pattern, the resulting FDR adjusted p-values must be regarded as
relative and not as unconditional probabilities indicating the
significance of association with exacerbation in general. Never-
theless, we report these ‘‘relative FDR p-values’’ because they help
identify significant changes between quiet and exacerbation observed
within subgroups, and because the values are useful for assessing
the relative strength and rank of each association.
Principal Components (PCA) Analysis
Principal components analysis (PCA) was used to display the
relationships among donor-visits in the 3 K-means clusters. PCA
was executed in Spotfire DecisionSite 9.0 (TIBCO, Palo Alto, CA).
Asthma Exacerbation Pathways
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Exacerbation-Associated Probe Sets Selection Criteria
We set the cut-offs for association with exacerbation within each
subgroup at relative FDR p-value ,0.05 and an absolute fold
change with exacerbation .1.2 fold. This fold change cut-off was
lower than conventional thresholds. Studies on selection of
appropriate fold change cut-offs in gene expression studies have
shown that decisions on cut-offs should take the characteristics of
individual dataset into account [16,17,18,19]. The relatively large
sample sizes in this study and the other considerations described in
the discussion are felt to justify the lower than conventional 1.2-
fold-cutoff.
Pathway analysis
Pathway analysis was performed using Ingenuity Pathways
Analysis (IPA) (www.ingenuity.com, Ingenuity Systems, Redwood
City, CA). Canonical pathways are shown as depicted by IPA, or
as expanded using the literature-based pathway building tools in
IPA. A right-tailed Fisher’s Exact Test was used to identify over-
represented functions or pathways in IPA. The p-values derived
through these analyses were based on: 1) number of functions/
canonical pathway eligible molecules that participate in that
annotation, 2) total number of knowledge base molecules known to
be associated with that function, 3) total number of functions/
canonical pathways eligible molecules, and 4) total number of
genes in the reference set (https://analysis.ingenuity.com/pa/
info/help/help.htm#ipa_help.htm).
TaqManH PCR
We have previously performed extensive analysis comparing
expression level data obtained using the Affymetrix U133A
GeneChip and TaqManH PCR and shown highly concordant
results. One of these platform concordance studies has been
reported previously [20]. The results of another study, using data
from some of the quiet asthma samples reported in this study, are
described in the Figure S2, and Text S1. The overall Pearson
correlation coefficient (for measurements of expression differences
by the two platforms) was 0.86. Due to this strong concordance,
we did not perform a GeneChip and TaqManH PCR platform
concordance analysis for the results reported here. However we
did use TaqManH PCR to measure levels of three specific genes,
IFNa1, IFNb1, and IFNc because these genes were expressed at
levels too low to be detected by the GeneChip, but were
functionally related to many genes identified from our GeneChip
data. We also measured IL13 by TaqManH PCR TaqManH
because of the association between the IL13 pathway and asthma.
Expression levels of these genes and ZNF592 (used for
normalization) were measured using primers, probes and instruc-
tions from Applied Biosystems (Table S3 and Text S1). ZNF592
was selected as a normalizer gene based on a survey of
oligonucleotide array expression data for 44,928 transcripts across
a compendium of 9,270 hybridizations, including multiple studies
involving different types of cells and tissues. In this broad survey,
ZNF592 had substantially less variability than other commonly
utilized endogenous controls. Specifically, ZNF592 had a
coefficient of variation which was at the 0.01-th percentile of
variation among all surveyed transcripts.
Results
Study Population
A total of 357 subjects were enrolled and are described in
Table 1 and Table S4. The mean FEV1 for each disease strata
(mild, moderate and severe) are shown in Table 2. Detailed
information on the enrolled subjects is reported in Text S1 with
the following parameter reported in tabulated form: assessment of
asthma control (Table S5), healthcare resource use (Table S6),
atopy status at screening (Table S7), body mass index and reflus
disease (Table S8), history of reflux disease (Table S9), change in
asthma severity by visit (Table S10), use of concomitant anti-
asthmatic medication (Table S11), use of anti-asthmatic medica-
tion by country (Table S12), healthcare resource use during course
of study (Table S13), precipitating and aggravating factors by visit
Table 1. Demographic and Baseline Characteristics by
Asthma Severity.
Characteristic Mild Moderate Severe Total
(n = 36) (n =149) (n =172) (N=357)
Mean age (yr) 41.14 43.4 47.37 45.08
S.D. 12.85 15.18 14.71 14.88
Female, n (%) 26 (72.2) 98 (65.8) 106 (61.6) 230 (64.4)
Male, n (%) 10 (27.8) 51 (34.2) 66 (38.4) 127 (35.6)
Asian, n (%) 0 (0) 4 (2.7) 6 (3.5) 10 (2.8)
Black, n (%) 1 (2.8) 11 (7.4) 24 (14.0) 36 (10.1)
White, n (%) 35 (97.2) 134 (89.9) 142 (82.6) 311 (87.1)
Hispanic, n (%) 0 (0) 3 (2.0) 10 (5.8) 13 (3.6)
Non-Hispanic, n (%) 36 (100) 146 (98.0) 162 (94.2) 344 (96.4)
Mean Weight (Kg) 78.03 82.01 80.87 81.06
S.D. 13.29 18.83 19.88 18.86
Mean Height (cm) 167.37 169.54 166.95 168.07
S.D. 10.39 10.08 9.47 9.88
Subjects were followed for 12 months according to site standard of care.
Twenty-seven subjects (7.6%) did not complete the study. The most common
reason overall for early withdrawal from the study was failure to return. The
most common reason for exclusion was FEV1 reversibility. The reasons for
patient exclusion tended to be site-specific rather than country-specific.
doi:10.1371/journal.pone.0021902.t001
Table 2. Mean FEV1 (% Predicted) at Scheduled Non-
Exacerbation Visits.
Exacerbation
Status Asthma Severity
Mild Moderate Severe
Never n 81 295 300
Mean 95.01 85.51 74.85
P-valuea ,0.0001
At Least 1 n 33 181 244
Mean 90.27 86.33 74.15
P-valuea ,0.0001
P-valueb 0.0479 0.5675 0.6851
All Subjects n 114 476 544
Mean 93.64 85.83 74.54
P-valuea ,0.0001
aP-value indicates test for differences among asthma severity groups
bP-value indicates test for difference between exacerbation status groups
(never had an exacerbation versus had at least 1 exacerbation) within an
asthma severity category.
Abbreviations: FEV1 = forced expiratory volume in 1 second.
doi:10.1371/journal.pone.0021902.t002
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(Table S14), adverse events (Table S15), most common respiratory
adverse events (Table S16), and mean FEV1 (% predicted) at
scheduled non-exacerbation visits (Table S17). To avoid potential
confounding effects of smoking, subjects who smoked (n= 20) were
excluded from the analyses reported here. Of 337 non-smoking
subjects (64.4% female, 87.1% white) enrolled, at least one
evaluable exacerbation sample was collected from each of 118
subjects, and there were 37 subjects from whom more than one
exacerbation sample was collected. The total number of exacerbation
samples analyzed was 166. From the 118 subjects from whom at
least one exacerbation sample was collected, a total of 394 quiet
samples and 125 follow-up samples were also collected (Figure 1
and Figure S1). The vast majority of exacerbation samples were from
severe (55%) and moderate (41%) asthmatics. The interval
between exacerbation onset and collection of the exacerbation
sample was unavoidably variable. Subjects were requested to go to
their doctor’s office within 3 days of the onset of the attack, with
72% of samples being collected within this window. For the 166
exacerbation samples reported in this study, 25% were collected on
the day of onset and 16%, 17%, 14%, 24% and 4% collected on
days 1,2, 3, 429, and 10214 post-exacerbation onset respectively.
Partitioning Exacerbation Samples into Three Subgroups
Gene expression levels in each subject in multiple quiet samples
were compared to levels in the same patient during individual
exacerbations by ANCOVA performed to determine the association
of each probe set with exacerbation. There were 1079 probe sets with
an unadjusted p-value association with exacerbation ranging from
5.33610210 to 561022 (0.05). Upon adjustment for multiplicity of
testing, however, the association with exacerbation was at an
unacceptably low confidence level for the majority of probe sets.
To gain an overview of the large dataset, we generated a heat map
of the difference between the log2 expression level during an
exacerbation visit and the mean log2 expression level during quiet
visits for the same subject for each of these 1079 probe sets for
each of the 166 exacerbation samples. As we had expected, this
analysis revealed significant heterogeneity of exacerbation-associated
gene expression patterns among the samples.
K-means clustering was performed to group the samples on the
basis of similarities in exacerbation-related differences. Since the K-
means algorithm partitions samples into the number of subgroups
stipulated by the investigator, procedures were performed to
determine the number of robust subgroups within the dataset. We
assessed the robustness of K-means clusters using both the
silhouette statistic (SW)[14] and a simulation-based robustness
index (R), similar to the approach of McShane et al.[15]. Figure
S3 shows silhouette statistics for K=2, 3, 4, and 8 clusters. There
is an ‘‘elbow’’ in the slope of the SW curve at K= 3, indicating that
further increases in K have diminishing benefits in distinguishing
distinct groups (Text S1). Figure S4 shows a clear and robust
separation into three subgroups (K= 3 clusters, SW=0.08,
R= 0.88). With more than 3 subgroups, the SW and R measures
of subgroup robustness declined, indicating no more than three
well defined subgroups of samples. Combining these observations
with the imperative to use the simplest model that is consistent
with the data, we selected K=3 (text S1). Exacerbation samples were
therefore partitioned by the K-means algorithm into three
subgroups designated X, Y and Z. Each exacerbation was assigned
by the algorithm to one of these three subgroups with the
subgroups comprising 18%, 38% and 43% of exacerbation samples
respectively. ANCOVA was performed and 1572 probe sets that
met the criteria for significant exacerbation association within any
subgroup were identified (FDR,0.05 and |fold change| .1.2 in
at least one subgroup). Separation of the subgroups using principal
component analysis is shown in Figure 2, and a heat map
representation ordered by bispectral clustering is shown in Figure
S5.
For Subgroups X, Y and Z, there were 1081, 574 and 286
probe sets respectively that met the criteria for significant
association with exacerbation. The FDR adjusted p-values for
association each of these subgroups are summarized in Figures 3,
4, 5, and Figure S6 of Text S1. Table S18 gives the identity of
each gene, the significance of the association with exacerbation,
and the log2 fold change with exacerbation. Separate ANCOVAs
comparing mean expression levels in quiet and follow-up samples
showed that, with a very small number (4%) of exceptions in
Subgroup Z, exacerbation–associated probe sets were not different
(relative FDR p-value.0.05) from quiet levels two weeks after
cessation of an exacerbation (Figures 3,4, and 5, and Figures S6).
These results show that: a) significant differences were detected in
gene expression in the blood of asthmatics during quiet and
exacerbation periods of disease, b) no significant differences were
Figure 1. Description of Study Samples. Of 357 subjects enrolled in the study, the 337 non-smoking subjects were selected for analyses of gene
expression patterns associated with exacerbation attack. A total of 118 subjects experienced at least one exacerbation attack, and 166 samples were
evaluated from these subjects. Analyses were performed comparing expression levels of each probe set in each exacerbation sample to the average
of quiet visits from the same subject.
doi:10.1371/journal.pone.0021902.g001
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identified when samples from individuals who were not experi-
encing exacerbation (follow-up samples) were compared to the
quiet sample dataset using identical procedures used in the analysis
with exacerbation samples. This latter point establishes that the
identification of differences in the quiet versus exacerbation
comparison cannot be attributed to unknown artifact(s) introduced
by conducting the analyses as described.
Detection of Exacerbation-Associated Genes and
Biological Pathways
Among Subgroup X genes, components of the toll-like receptor
(TLR) and interferon response signaling pathways were signifi-
cantly over-represented (Figure 6). P-values determined by
Ingenuity Pathway Analysis for significance of over-representation
of interferon and TLR pathways are = 4.2361028 and 2.6661022
respectively. Interferon-inducible genes that were over-expressed
included the interferon regulatory factors (IRFs) 21, 27 and 29
(Figure 7). IRF-4 was down-regulated as were its target genes
(Figure 8). Pathway analysis indicated a role for either IFNa1,
IFNb1, and IFNc in exacerbation, but these three genes were below
detectable levels using the HG-U133A Affymetrix GeneChip
ArrayH. As a result, expression levels of these three genes were
measured TaqManH PCR. In Subgroup X, significant elevation of
mRNA for type I interferons IFNa1 (p = 4.7610
23) and IFNb1
(p = 3.161023) was observed, while the association with the type II
interferon (IFNc)was not significant, indicating that the activation
of IFN associated genes was being driven by type I interferon.
Figure 2. Principal Component Analysis Showing Separation of
Subgroups X, Y and Z. PCA was performed on the log-ratios of
exacerbation to quiet expression levels for 1,572 probesets measured in
166 donor-visits. The cumulative percent of variation explained by
principal components 1, 2, and 3 was 23%, 37%, and 43% respectively;
components 1 and 2 are shown in the figure.
doi:10.1371/journal.pone.0021902.g002
Figure 3. Association of Subgroup X Probe Sets with Exacerbation. Relative FDR p-value for 1081 probe sets meeting selection criteria in
ANCOVA on 30 Subgroup X exacerbation samples compared to the average of their corresponding quiet samples. To clarify the visual representations,
probe sets have been ordered by descending relative FDR p-value in the comparison of quiet versus exacerbation samples. The metrics associated
with each of the 1081 probe sets are given in the Table S18. See Figure S6 for results obtained from ANCOVA comparing quiet and exacerbation using
only the 22 exacerbation samples with corresponding follow-up sample.
doi:10.1371/journal.pone.0021902.g003
Asthma Exacerbation Pathways
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21902
Figure 4. Association of Subgroup Y Probe Sets with Exacerbation. Relative FDR for 574 probe sets meeting selection criteria in ANCOVA of
64 Subgroup Y exacerbation samples and the average of their corresponding quiet samples. See Table S18 for metrics for each individual probe set,
and Figure S6 for results obtained comparing quiet and exacerbation using only the 55 exacerbation samples with corresponding follow-up sample.
doi:10.1371/journal.pone.0021902.g004
Figure 5. Association of Subgroup Z Probe Sets with Exacerbation. Relative FDR for 286 probe sets meeting selection criteria in ANCOVA of
72 Subgroup Z exacerbation samples and the average of their corresponding quiet samples. See Table S18 for metrics on individual probe sets and
Figure S6 for results comparing quiet and exacerbation using only the 52 exacerbation samples with corresponding follow-up sample.
doi:10.1371/journal.pone.0021902.g005
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One of the genes regulated by IRF7 is IL15, and a network
centered on IL15 was found to be highly significant in Subgroup
X. Ingenuity Pathway Analysis determined the significance of
over-representation of IL15-regulated genes at p = 4610213,
indicating a role for this cytokine in the expression of several
exacerbation-related genes (Figure 9 and Table S19). Consistent
with the TCR-independent activation of T cell by IL15 [21], there
was down-regulation of the TCR activation pathway in Subgroup
X (Text S1, Table S18). These results support the dominant
involvement of innate immune pathways in Subgroup X.
In contrast to the dominant signatures of innate immunity
detected in Subgroup X, the gene expression patterns in Subgroup
Y were indicative of a dominant role of antigen driven pathways of
adaptive immunity. Genes associated with the activation of B cells
through the B cell antigen receptor were more significantly
upregulated in Subgroup Y than in the other subgroups
(Figure 10). Ingenuity Pathway Analysis determined the signifi-
cance of over-representation of B cells antigen receptor pathway in
Subgroup Y at p= 3.5461023. While genes of the T cell receptor-
dependent pathway were down-regulated in Subgroup X, the
same genes were significantly up-regulated in Subgroup Y
(Figure 11). Ingenuity Pathway Analysis determined the signifi-
cance of over-representation of T cells receptor pathway genes in
Subgroup Y at p= 1.561022. Genes of the IL4 pathway, a
pathway with well established links to asthma [22,23], were also
over-represented in Subgroup Y (p = 6.261023). Because IL13
was not detectable by GeneChip and is known to be an important
mediator of lung inflammation and IgE production [24,25,26,27],
IL13 expression levels were measured in a small subset of samples
by TaqManH PCR. We did not detect a significant difference
between quiet and exacerbation samples within any of the subgroups.
Compared to the other subgroups, the genes associated with
exacerbation within subgroup Z were far fewer and of less statistical
significance (Figures 5). There were 674 probe sets in Subgroup X
and 110 in Subgroup Y that exhibited more significant
associations with exacerbation than the most significant associations
seen in Subgroup Z. Since Subgroup Z is the largest of the 3
subgroups in terms of number of samples, the comparatively weak
signature cannot be attributed to lack of statistical power. Of the
286 probe sets in Subgroup Z with significantly altered expression
relative to quiet visits, only 26% (75) of the 286 probe sets were
unique to Subgroup Z, and this relatively short list of genes was
not sufficient for an informative pathway analysis. In the majority
of cases where Subgroup Z genes overlapped with those of
Subgroup X and/or Y, the association with exacerbation in
Subgroup Z was much less significant, again indicating that the
Subgroup Z expression pattern is weak by comparison to the other
subgroups.
Figure 6. Activation of the TLR Pathway in Subgroup X. Genes that are significantly upregulated in exacerbation are shown in red.
doi:10.1371/journal.pone.0021902.g006
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Search for Subgroup Assignment and Clinical Parameters
Associations
We examined whether multiple exacerbations from the same
subject were assigned to the same subgroup, and for 19 subjects
this was not the case. Therefore, subgroup assignment was not
solely attributable to an invariant parameter associated with the
subject. The time between exacerbation onset and collection of the
exacerbation sample varied from 0 to 14 days, but the subgroups did
not differ with respect to this parameter (Table 3, Figure S7 and
Text S1). Due to the non-normal distribution of days from start, a
non-parametric version of a standard ANOVA was run, and no
evidence of differences among clusters in mean days from start was
observed (p-value = 0.49 in test for differences of means among
clusters, calculated from a one-way ANOVA run on the ranks.)
Multiple analyses were performed to identify any associations
between subgroup assignment and respiratory function and no
associations were identified. For these analyses respiratory function
was assessed by FEV1 predicted (Table S20), FEV1 change from
baseline (Table S21), FVC predicted (Table S22), FVC change
from baseline (Table S23), FEF 25–75% predicted (Table S24),
FEF 25–75% change from baseline (Table S25), PEF predicted
(Table S26), PEF change from baseline (Table S27) or relevant
respiratory infection (Table S28). There was also no association
between cluster assignment and disease severity (Table S29).
Cluster assignment also did not show an association with use of
medications such as systemic corticosteroids (Table S30), inhaled
corticosteroids (Table S31), intranasal corticosteroids (Table S32)
leukotriene antagonists (Table S33), any GI medication use (Table
S34), any PPI medication use (table S35), or any histamine H2
antagonist (Table S36). Analysis also failed to identify an
association between subgroup assignment and sex (Table S37),
race (Table S38), location of sample processing (Table S39),
country (Table S40), atopy status (Table S41), fasting status (Table
S42), IgE levels (Table S43) or history of acid reflux (Table S44).
Of the 27 analyses run in an effort to identity associations
between subgroup assignment and other parameters, two analyses
identified significant associations. Mean BMI was statistically
significantly lower (p = 0.006) in Subgroup X than Subgroup Y,
and statistically suggestively lower (p = 0.0501) in Sub-group Z
than in Subgroup Y (Table S45). This finding indicates that those
with the highest BMI tended to be preferentially assigned to
Subgroup Y. As discussed below, this finding is notable in light of
Figure 7. Activation of the Interferon Pathway in Subgroup X. Type I and Type II interferon-induced genes including IRFs that are involved in
the regulation of interferon response, and the JAK-STAT signaling components of the IFN signaling pathway that are upregulated in Subgroup X
exacerbations are shown in red.
doi:10.1371/journal.pone.0021902.g007
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the report from Haldar et al. [28] that obese non-eosinophilic
asthmatics constitute a cluster of asthmatics that differ from other
types of asthmatics with respect to clinical response to treatment.
The other parameter that showed a significant association with
subgroup assignment was the time between quiet visit and
subsequent exacerbation visit (Table 4 and Table S46). There
was a significantly shorter time between a quiet visit and the
subsequent exacerbation visits for samples in Subgroups X and Y
(median days 40.5 and 40 respectively) than for samples in
Subgroup Z (median days 69).
Discussion
The elucidation of mechanisms that drive naturally occurring
human asthma exacerbations presents a considerable translational
medicine challenge in this area of unmet medical need. We have
conducted a multinational study and searched for changes in
PBMC gene expression coincident with asthma exacerbation. The
approach we have taken was intended to test whether advances in
understanding could be made in the absence of pre-conceived bias
by using the broad net of expression profiling and bioinformatics
approaches. The strengths of our study are its large size,
longitudinal design, recruitment of patients from multiple sites in
the Northern and Southern Hemisphere and collection of samples
from individual subjects during multiple quiet, naturally occurring
exacerbation and follow-up periods in real-life settings.
From the start, it was recognized that, even if exacerbation
associated gene expression patterns existed in the blood, they
were likely to be heterogeneous. This prediction was based on the
known complexity and heterogeneity of asthma and asthma
exacerbations, the multiple triggers associated with natural
exacerbations, and the knowledge that many sources of variability
could not be controlled in a study of naturally occurring
exacerbations. Adding to these challenges was the realization
that, prior to study initiation, we had little information on what to
base predictions of the strength signal(s) or the degree of sample
Figure 8. Activation of the Interferon Response Factors in Subgroup X. Several genes upregulated in Subgroup X exacerbations are
controlled by IRFs and are shown in red. In addition to IRF1, IRF7 and IRF9 are up-regulated in exacerbation along with the target genes that these
IRFs regulate. IRF4 is down-regulated (as shown in green) and this change is consistent with the changes observed in IRF4-target genes. IRF1 appears
to be the major driver of gene expression changes in Subgroup X. IRF1 is also involved in the regulation of IL15 expression.
doi:10.1371/journal.pone.0021902.g008
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heterogeneity. Therefore, the study design and data analysis plans
contained elements aimed at maximizing the chances of detecting
changes in gene expression that could, with a high level of
confidence, be attributed to exacerbation. First, the number of
subjects enrolled was as large as we could accommodate in a
study which depended on high content oligonucleotide arrays.
From the total of 337 enrolled subjects, 166 exacerbation samples
from 118 subjects who had at least one exacerbation attack were
collected. Secondly, the average number of quiet samples collected
over the course of a year from each of these exacerbating subjects
was 3.3, enabling determination of the variability in level of
expression of each gene in each subject during quiescent asthma
over the course of approximately one year. These multiple quiet
samples for each subject served as the control comparators for a
sample or samples drawn from the same subject during
exacerbations. ANCOVA probed for differences in each exacerbation
sample as compared to the levels observed in quiet samples from
the same subject. Covariate analysis adjusted for effects associated
with many covariates including steroid use, age, sex, and cell
differentials. Thirdly, data-driven clustering algorithms that
operate without investigator bias were employed to characterize
the heterogeneity of exacerbation-related expression patterns,
and determine the number of well defined subgroups within the
dataset.
Figure 9. Modulation of the IL15 Pathway in Subgroup X. Many IL15-induced genes are significantly modulated in Subgroup X, and this
network is also identified by Ingenuity Pathway analysis as a significant pathway among Subgroup X genes. Red indicates genes up-regulated in
exacerbation and green indicate genes down-regulated in exacerbation. See Table S5 for a complete list of IL15 pathway genes associated with
exacerbation.
doi:10.1371/journal.pone.0021902.g009
Asthma Exacerbation Pathways
PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e21902
The study design enabled the identification of changes in
PBMC gene expression coincident with asthma exacerbation.
Our first pass analysis on the complete sample set indicated an
exacerbation-associated gene expression pattern encompassing a
large number of genes most of which, on an individual basis,
were associated with exacerbation at an unacceptably low
confidence level. We examined the expression pattern of all
samples using the 1079 probe sets associated with exacerbation
with a low level of confidence (unadjusted p-value,0.05), and
used that data to examine the heterogeneity among samples.
The heterogeneity revealed by this analysis indicated that the
relative statistical weakness of the associations identified by
ANCOVA was explained by differences among samples with
respect to exacerbation-associated fold change in gene expres-
sion. Clearly, the heterogeneity within the group of exacerbation
samples as a whole masked much of the information that could
be garnered by analyzing the less heterogeneous subgroups of
samples.
Figure 10. Modulation of the B Cell Antigen Receptor Pathway in Subgroup Y. Shown in red are B-cell receptor signaling pathway
components that are up-regulated in Subgroup Y exacerbations.
doi:10.1371/journal.pone.0021902.g010
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It must be recognized that it would not be possible to avoid
many of the sources of variability inherent in a yearlong
observational study of naturally occurring exacerbation in subjects
living their normal lives. For example the interval between
exacerbation onset and sample collection varied from 0 to 14 days.
A number of other variables would be predicted to affect results
including, but not limited to, severity of underlying disease,
severity of exacerbation attack, patient disease phenotype, timing
and type of medication, type of trigger, and level of exposure to
trigger. The interactions between these variables would also be
predicted to affect results. Each exacerbation sample should therefore
be viewed as a single time point ‘‘snap-shot’’ of a disease state that
is influenced by many covariates and waxes and wanes due to the
natural course of exacerbation resolution and the effects of
therapy. It was our hypothesis that, if exacerbation-associated
expression changes occurred in blood, heterogeneity of expression
patterns would be observed. The size of the study reflected this
Figure 11. Modulation of the T Cell Antigen Receptor in Subgroup Y. Shown in red are T-cell receptor signaling pathway components that
are up-regulated in Subgroup Y exacerbations.
doi:10.1371/journal.pone.0021902.g011
Table 3. Subgroup Assignment and Days Between
Exacerbation Onset and Collection of Exacerbation Sample.
Subgroup
X Y Z
Number of exacerbation visit samples 30 64 72
Median number of days between onset and sample collection 2 2 2
Minimum number days 0 0 0
Maximum number of days 9 14 12
Quartile 1 0 0 1
Quartile 3 2.8 4.0 3.3
doi:10.1371/journal.pone.0021902.t003
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hypothesis, and we took the risk that the study was sufficiently
large to allow an examination of heterogeneity.
We proceeded with K-means clustering to partition samples on
the basis of similarity of exacerbation-related gene expression
pattern. Because the number of groups into which K-means
partitions samples is specified by investigator, we performed a
series of analyses to ascertain separability and robustness, which
measure how distinct the subgroups are from each other. Based on
the outcome of these analyses, we concluded that the samples
should be subdivided into three groups. K-means analysis was then
used to assign each of 166 exacerbation samples to 1 of 3 subgroups.
The direct consequence of grouping samples on the basis of
similarity in exacerbation related changes was a reduction in
variability within each subgroup. As a direct consequence of the
reduced variability, ANCOVA run on samples categorized by
subgroup identified many more genes that were associated with
exacerbation within an acceptable confidence limit (relative
FDR,0.05). The exacerbation samples in subgroups X and Y
showed many robust differences with the quiet samples. The
exacerbation samples in Subgroup Z (44% of exacerbation samples)
showed much less profound differences with quiet. These results
suggested that the relatively weak exacerbation-associated expression
pattern in Subgroup Z greatly diminished the ability to detect
exacerbation-associated genes when all the samples were analyzed as
a whole.
Choosing gene selection criteria in studies using oligonucleo-
tide arrays poses significant challenges that cannot be met simply
by using cut-offs adopted by convention [16,17,18,19]. While the
1.2 fold change cut-off chosen was low in comparison to
convention, the large size of study reported here provided better
statistical power than usually available in GeneChip-based
translational medicine studies of mixed cell populations. Our
choice of the 1.2 fold change cut-off was based on the following
three considerations. First, we examined the relationship between
fold change and relative FDR p-value in this particular dataset
and observed that a high proportion of probe sets with fold
change between 1.2 and 1.3 also had a relative FDR p-value
,0.05. This was not the case for probe sets with fold change
between 1.1 and 1.2. For example, in the analyses of Subgroup
X, 70% of probe set with fold change between 1.2 and 1.3 were
significantly associated with exacerbation (relative FDR p-value
,0.05). Exclusion of these probe sets from the analysis of
biological pathway involved would have diminished the informa-
tion on the representation of various pathways within the dataset.
Our goal was to address the biology and probe the pathways that
are dysregulated in exacerbation, and slight but significant fold
changes of several genes within a given pathway provided
cumulative evidence implicating the pathway. Consistent with
this analytical approach we note that any impact of false positive
identifications would be mitigated by a lack of cumulative
evidence provided by functionally related genes. A second
consideration in setting the fold change cut-off at 1.2 was that
statistically significant but small changes in magnitude were of
biological interest. The profiles were generated using the mixed
population of cells in the periphery, and therefore a large
magnitude change in one, perhaps minority, cell population
would be expected to have a diluted impact on the average fold
change observed in the population as a whole. The third source
of support for the 1.2 fold cut-off decision was obtained from a
GeneChip study comparing quiet asthma samples to healthy
volunteer samples. We selected 24 pairs of samples and used a
custom low density TaqManH array to measure the fold change
of 192 genes by TaqManH PCR. The fold change between
samples by GeneChip was below 1.2 for a significant number of
gene/sample pair combinations. We compared the log2 signal
differences obtained by GeneChip to the delta CT differences
obtained by TaqManH. Results between platforms were concor-
dant in 87% of the comparisons performed, and lack of
concordance was associated with low expression level, and not
with low fold change (O’Toole, Burczynski et al. unpublished
data). We recognize that by imposing the fold change filter in
addition to the relative FDR p-value criteria some true positives
have most likely been excluded (especially among the few probe
sets with fold change ,1.2 and very low relative FDR p-values)
and some false positives included (especially among probe sets
with low fold change and relative FDR p-value close to the 0.05
cut-off), but based on the three considerations described here, the
1.2 fold cut-off was the most appropriate cut-off for this study.
The size of the study and distribution of the expression values
were sufficient to allow definition of three robust subgroups of
exacerbation-associated gene expression profiles. Key validation that
analytical methods and selection criteria used had identified genes
associated with exacerbation in each of the individual subgroups
was obtained when the intra-subgroup ANCOVA comparison of
quiet and follow-up samples did not identify significant differences.
Thus, ANCOVA did not merely identify highly variable genes
that, by random chance, differed significantly between the
exacerbation set of samples and quiet set of samples.
Examination of the known biological links between exacerbation-
associated genes led to our conclusions that systemic immune
pathways are extensively activated during asthma exacerbations.
Innate and antigen-independent immune pathways were predom-
inantly activated in subgroup X, with toll-like receptors TLR1,
TLR2 and TLR4 being significantly elevated (Figure 6). Cell
activation through TLRs is a well established driver of type I
interferon responses. Because interferon genes were not themselves
detectable by GeneChip, TaqManH PCR assays were done to
confirm significant elevation of Type I interferon genes. The
importance of this innate immune response was reinforced by the
finding of extensive interferon pathway activation associated with
Subgroup X and extensive activation of many interferon inducible
genes such as OAS1, OAS3, MX1, and IFITM3 as well as the
interferon regulatory factors IRF 1,7 and 9 (Figure 7). Taken
together these data indicate that in Subgroup X, TLR activation
leads to induction of a systemic type I interferon response.
Table 4. Association Between Subgroup Assignment and
Days Since Exacerbation Visit and Previous Quiet Visit.
Subgroup based on 1079 probeset clustering
Statistic Subgroup X Subgroup Y Subgroup Z
N 30 64 71
Mean 48.4 62.7 79.6
Median 40.5 40 69
S.D. 45.3 55.3 64.0
CV 93.6 88.3 80.5
5th percentile 9 7 11
95th percentile 91 181 211
Missing values 0 0 1
Differences between nodes in mean number of days since quiet visit.
Exacerbation visits occur sooner after a quiet visit in some nodes than in others.
Statistically significant difference between Subgroups 1 and 3 (p = 0.014),
difference between Subgroups 2 and 3 is statistically suggestive (p = 0.091.
p-value from test for differences of means among Subgroups = 0.03.
doi:10.1371/journal.pone.0021902.t004
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It is well established that infection triggers activation of the
innate immunity pathways, and that type I interferon response is
closely linked to viral infection via activation of TLR-3 and -7/-8
by ss- and ds-RNA respectively [29,30]. An important question,
but one beyond the scope of this study, is how do the peripheral
blood expression profile changes seen in asthmatics during
respiratory infection differ from the changes seen in non-
asthmatics during respiratory infection? Since respiratory infec-
tions are a common trigger of asthma exacerbations [31], a study
that identifies differences between asthmatics and non-asthmatics
in pathways activated during respiratory infections could advance
understanding of the disease. Among the utilities of this study is
that it has laid a foundation showing the feasibility and likely
fruitfulness of such a study.
It has been reported in normal subjects that during viral upper
respiratory tract infection in the absence of lower respiratory tract
involvement, there is no systemic interferon response [32]. This
finding contrasts with our results on robust systemic interferon
activation signature in the blood of exacerbating asthmatics - both
infected and without symptomatic evidence of infection. One
possible explanation for these differing results is that homing
processes may be at least somewhat abnormal in asthmatics.
Inappropriate homing could promote virus proliferation in the
lower airways, cytotoxic injury and entry into the circulation as has
recently been shown in childhood asthma exacerbation [33]. A
recent study using Illumina Human Bead Chip arrays applied to
PBMCs compared expression during exacerbations in dust mite
sensitive asthmatic children to expression in stable asthma and
normal controls. That study found that many of the asthma
exacerbation related genes were involved in defense responses and
responses to external stimuli, but these associations disappeared
after excluding infection related genes [34]. However, this study
was much smaller (N= 12 exacerbation samples) than the study
reported here (n = 166 exacerbation samples).
An unexpected finding was that a large proportion of the
exacerbation samples with the robust signature of innate immune
activation were from patients for whom symptoms of respiratory
infection were not reported by the patient nor noted by the
physician. Among possible explanations for this are: a) pathogen
load too low to result in commonly recognized symptoms of
infection but sufficient to trigger innate immunity in asthmatics, or
b) triggering through TLR ligands such as reactivated bacteria
[35], resident viruses [36], biologically active allergens such as Der
P2 [37] or ambient air pollutants as encountered in an air
pollution episode [38,39]. Indeed many endogenous molecules
that are increased with inflammation are TLR ligands and
agonists [40,41,42,43,44], and in mice the immunostimulatory
activity of lung surfactant protein A is TLR4-dependent [45].
Therefore the molecules that activate innate immunity may be of
either pathogen or host origin, and the strong signature of innate
immunity implicates innate immunity in exacerbation even in the
absence of symptoms of respiratory infection. This interpretation
fits with the accumulating evidence that innate immunity plays an
important role in asthma [46,47,48,49,50,51] and with the
findings of association between asthma and single nucleotide
polymorphisms in TLRs [52,53,54,55,56] and associated mole-
cules [57,58,59,60,61].
Another prominent characteristic of Subgroup X exacerbations
was a highly significant representation of IL15-pathway genes.
IL15 production is known to be strongly induced by interferons
[62], transcriptionally activated by IRF-1 [63], supports a non-
TCR–mediated T-cell response [21] and results in activation of
CD8 T cells [64]. IL15 has also been linked to asthma and allergy
by DNA polymorphism association [65,66]. These reports are
consistent with our findings on the down-regulation of the TCR
pathway in Subgroup X. This study implicates IL15 as a bridge
between innate and adaptive immune responses in asthma
exacerbation.
Subgroup Y genes that increased during exacerbation
included those involved in B-cell activation pathway through
B-cell antigen receptor (BCR) and the IL4 signalling pathway
involved in inducing and maintaining pro-allergic Th-2 cell and
IgE responses [22,23]. These responses are linked to a strong
adaptive allergen-driven immune response, and distinguish
Subgroup Y exacerbations from the innate immunity pathways
that dominated the gene signature of Subgroup X. While the
signatures of innate immunity did not predominate in Subgroup
Y as they did in Subgroup X, NK signalling was significant in
both subgroups, with more activation detected in Subgroup Y.
Overlap with Subgroup X was observed for 24% of Subgroup Y
probe sets, and for all but 3% (centered on antigen receptor
mediated pathways), the direction of change with exacerbation was
the same in Subgroups X and Y. These observations, together
with the important role innate immunity is known to play in
priming adaptive immunity [67], suggest a complex interplay
between both these arms of the immune system during the
course of an asthma exacerbation. Consistent with this view are
the examples in this study of predominance of innate immune
pathways at a single sampling point during one exacerbation,
and predominance of adaptive immune pathways at a single
sampling point during a different exacerbation from the same
patient.
Subgroup Z comprised the largest number of samples, but also
contained the exacerbation samples that differed least from the quiet
samples, both in terms of the number of differentiating probe sets
(286) and the significance of the detected differences. A number of
the probes-sets identified in Subgroup Z overlapped with probe
sets in the other subgroups, but the significance of the association
was almost always much less in subgroup Z. Also the direction of
change was often in opposite direction, perhaps suggesting that
these exacerbations were sampled at a time when homing between
periphery and tissue was at a different phase. Pathway analysis on
the 75 genes uniquely identified in Subgroup Z unfortunately did
not identify any dominant biological processes. We did not seek to
determine if reduction in stringency of selection criteria would
have pointed towards particular pathway(s). Such a relaxation of
the standards might have given hints implicating various biological
pathways, but would also have resulted in identification of a large
number of confounding false positives.
Extensive analysis was conducted in a search for parameters
associated with the assignment by K- means of a particular
exacerbation sample to a particular subgroup. Exacerbation samples
from a single donor were not necessarily assigned to the same
subgroups, indicating that subgroup assignment cannot be solely
determined by an invariant characteristic of the patient.
However, the relatively stable patient characteristic of BMI had
a significant association with subgroup assignment. Mean BMI is
statistically significantly lower (p = 0.006) in Subgroup X than
Subgroup Y, and is statistically suggestively lower (p = 0.0501) in
Sub-group Z than in Subgroup Y. These results suggest that
subjects with lowest BMI tended to have the most pronounced
pro-inflammatory gene expression profile. The gene expression
changes observed in the group with the significantly higher BMI
tended to be of less magnitude, and with less evidence of
involvement of the innate immune system than those in Subgroup
X. Haldar et al [28] have reported that those of an obese non-
eosinophilic asthmatic phenotype tended to cluster based on
similarities in clinical parameters such as response to therapy.
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The authors suggested that, based on differences between the
obese and other groups observed in the parameters they studied,
the difference between the obese group and the other groups
‘‘may provide a reliable framework for exploratory molecular and
genetic studies, presently undermined by population heterogene-
ity’’. The patients in Subgroup Y of this study have lower mean
BMI (32.4) than the obese group in the Haldar et al study (36.2),
but the finding of a BMI influence on asthma phenotypes is
common to both studies.
The comparative weakness of the gene expression signature in
Subgroup Z led us to a number of hypotheses which were then
tested by calculating the significance of association between
subgroup assignment and a given clinical parameter. For instance
there was no association between subgroup assignment and: 1)
severity of exacerbation as indicated by spirometry, 2) asthma
severity level, 3) time between exacerbation onset and sample
collection, 4) physician noted symptoms of respiratory infection, 5)
medication use 6) ethnicity, or 7) country of residence. A
hypothesis to explain subgroup assignment that is not ruled out
by the available data is that some combination of these covariates
acts together to influenced subgroup assignment. We did not have
information on some potentially relevant covariates such as the
level of exposure to exacerbation trigger and the degree of
sensitivity to various triggers. The study was not large enough to
support combinatorial analyses on the data available for other
covariates. The available information has not provided insight into
how to predict which exacerbation-associated gene expression
pattern described here would be expressed by any particular
exacerbation sample. One covariate identified as significantly
associated with subgroup assignment was the mean number of
days between quiet and exacerbation visits. As shown in Table 4,
there was a shorter time between a quiet visit and the subsequent
exacerbation visit for samples in Subgroups X and Y (median days
40.5 and 40 respectively) than for samples in Subgroup Z (median
days 69). The time interval between visits for Subgroup Z (median
69 days, average 79.6 days) indicates that many Subgroup Z
exacerbations occurred within the window of a scheduled quiet
visit. It therefore seems likely that the explanation for this longer
interval in Subgroup Z was that these exacerbation samples came
from patients less likely to have sought urgent care for the
exacerbation, but nevertheless met the study criteria for exacerbation
visit. We hypothesize that, although the severity of these
exacerbations did not differ with respect to the objective measures
captured in the database, the patients felt less impacted by
Subgroup Z exacerbations than by exacerbations assigned to
either of the other two subgroups. This hypothesis is consistent
with the molecular profile showing a much diminished exacerbation
molecular signature in Subgroup Z. Also consistent with this
interpretation of the data is that Subgroup Z exacerbations may
represent a type of exacerbation that slowly worsens, while
Subgroup X and Y exacerbation more acutely impact the patient,
and have a shorter ‘‘build-up’’ phase.
This study has provided proof of concept that systemic
changes associated with asthma exacerbation can be studied in
the blood. In addition to showing that the involvement of
biological processes with well-established roles in asthma can be
detected in the blood, the study has also provided new insights
such as the significant involvement of the IL15 pathway, and
activation of innate immune pathways in the absence of
apparent symptoms of respiratory infections. Perhaps the
greatest impact of our study will come from the foundation it
has laid for future studies, in particular comparative studies
between healthy and asthmatic subjects during the course of
respiratory infection. Further investigation could also be aimed
at an understanding of transitions in gene activation that occur
over the course of an exacerbation, from initiation to resolution.
These type of data could be targeted at a selected set of genes,
and seek to distinguish between processes that exacerbate
disease, and processes that are actually associated with the
resolution of such exacerbations.
Supporting Information
Figure S1 Distribution of 384 Quiet Samples from 118
Subjects. Three or more quiet samples were analyzed from the
majority (84%) of the 118 subjects with exacerbation samples, with 3
samples from 38% of subjects, 4 samples from 40% of subjects,
and 5 samples analyzed from 6% of subjects. Two quiet samples
were analyzed from 12% of the subjects, and only 1 quiet sample
was available for the remaining 3%.
(DOC)
Figure S2 Concordance of Results Using GeneChip and
TaqManH Platforms. A strong correlation was observed
between expression levels as measured by Affymetrix U133A
GeneChip and as measured by TaqManH Low Density Array.
Differences in expression between paired samples as observed in
the two platforms are shown. Signal sample pair differences (log 2
from GeneChip) are shown on the X axis, and delta CT sample
pair differences (from TaqManH) on the Y axis.
(DOC)
Figure S3 Silhouette Statistic. The silhouette statistics for
K=2, K=3, K=4 and K=8 are shown.
(DOC)
Figure S4 Robustness Statistics. The larger drop in
robustness statistic (R) from K=3 to K=4, compared to either
the K=1–2 or K=4–8 drops, is shown indicating that increasing
from 3 to 4 clusters markedly reduced the robustness of the cluster
assignments to simulated experimental noise.
(DOC)
Figure S5 Visual Representation (Heat Map) Of Exac-
erbation Related Gene Expression differences. Color
representation of differences between gene expression levels in
each of 166 exacerbation samples and the average of quiet samples
from the same patient. Intensity of color indicates magnitude of
exacerbation/average quiet log ratios. Red color indicates
elevation in expression in exacerbation, and green represents a
decrease.
(DOC)
Figure S6 Relative FDR p-value Obtained From AN-
COVA. A. Subgroup X Samples Using Only Exacerbation
Samples with Corresponding Follow-up Sample. Comparison of
relative FDR p-values for association with exacerbation obtained
using N=30 exacerbation samples and N=22 exacerbation samples
for which a follow-up sample was available. As expected, there is
in general a small reduction in significance with the smaller sample
number, but relative FDR p-values are very similar. B. Relative
FDR p-value Obtained From ANCOVA On Subgroup Y Samples
Using Only Exacerbation Samples with Corresponding Follow-up
Sample.Comparison of relative FDR p-values for association with
exacerbation obtained using N=64 exacerbation samples and
N=51 exacerbation samples for which a follow-up sample was
available. As expected, there is in general a small reduction in
significance with the smaller sample number, but relative FDR p-
values are very similar. C. Relative FDR p-value Obtained From
ANCOVA On Subgroup Z Samples Using Only Exacerbation
Samples with Corresponding Follow-up Sample. Results of
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ANCOVA indicate the lack of a robust gene expression pattern (in
comparison to Subgroups X and Y) associated with Subgroup Z
exacerbations. In the analysis using the 52 exacerbation samples
for which a corresponding follow-up sample was available, the
FDRs in the Quiet versus Exacerbation analysis is, as expected, less
significant than the FDRs obtained with the larger sample set
(N= 72).
(DOC)
Figure S7 Subgroup Assignment and Days Between
Exacerbation Onset and Exacerbation Sample Collec-
tion. Results (in box plot format) of analysis showing lack of
association between days between exacerbation onset and
collection of exacerbation sample.
(DOC)
Table S1 Post-CPT purification monocyte and lympho-
cyte percent in quiet and exacerbation visits.
(DOC)
Table S2 Quality control criteria for inclusion of
GeneChip in analysis.
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Table S3 Genes analyzed by Taqman with assay
identification.
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Table S4 Demographic and baseline characteristics by
asthma severity.
(DOC)
Table S5 Global assessment of asthma control by the
subject and by the investigator at screening.
(DOC)
Table S6 Reported asthma healthcare resource use
before enrollment.
(DOC)
Table S7 Atopy status at screening.
(DOC)
Table S8 Body mass index and gastrointestinal reflux
disease.
(DOC)
Table S9 History of reflux disease.
(DOC)
Table S10 Subjects with change in asthma severity by
visit.
(DOC)
Table S11 Number (%) subjects who used concomitant
anti-asthmatic medications by asthma severity.
(DOC)
Table S12 Number (%) of subjects who used concom-
itant anti-asthmatic medications by country.
(DOC)
Table S13 Reported asthma healthcare resource use
during the study.
(DOC)
Table S14 Asthma precipitating or aggravating factors.
(DOC)
Table S15 Number (%) of subjects experiencing adverse
events.
(DOC)
Table S16 Most common ($10% of subjects in any
severity group) respiratory adverse events, number (%)
of subjects.
(DOC)
Table S17 Mean FEV1 (% predicted) at scheduled non-
exacerbation visits.
(DOC)
Table S18 ANCOVA results. A: subgroup X. B: sub-
group Y C: subgroup Z.
(DOC)
Table S19 IL15 pathway genes associated with exacer-
bation in subgroup X.
(DOC)
Table S20 Lack of subgroup association with FEV1
predicted.
(DOC)
Table S21 Lack of subgroup association with FEV1
(predicted) change from baseline.
(DOC)
Table S22 Lack of subgroup association with FVC
(predicted).
(DOC)
Table S23 Lack of subgroup association with FVC
(predicted) change from baseline.
(DOC)
Table S24 Lack of subgroup association with FEF 25–
75% (predicted).
(DOC)
Table S25 Lack of subgroup association with FEF 25–
75% (predicted) change from baseline.
(DOC)
Table S26 Lack of subgroup association with PEF
(predicted) change from baseline.
(DOC)
Table S27 Lack of subgroup association with PEF
(predicted) change from baseline.
(DOC)
Table S28 Lack of subgroup association with relevant
respiratory infection.
(DOC)
Table S29 Lack of subgroup association with disease
severity.
(DOC)
Table S30 Lack of subgroup association with use of
medication: systemic corticosteroids.
(DOC)
Table S31 Lack of subgroup association with use of
medication: inhaled corticosteroids.
(DOC)
Table S32 Lack of subgroup association with use of
medication: intranasal corticosteroids.
(DOC)
Table S33 Lack of subgroup association with use of
medication: leukotriene antagonists.
(DOC)
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Table S34 Lack of subgroup association with use of
medication: Any GI non-study medication use.
(DOC)
Table S35 Lack of subgroup association with use of
medication: Any PPI non-study medication use.
(DOC)
Table S36 Lack of subgroup association with use of
medication: any histamine H2 antagonist non-study
medication use.
(DOC)
Table S37 Lack of subgroup association with sex.
(DOC)
Table S38 Subgroup assignment is not associated with
race.
(DOC)
Table S39 Subgroup assignment is not associated with
laboratory in which the samples were processed.
(DOC)
Table S40 Subgroups assignment is not associated with
patients’ country of residence.
(DOC)
Table S41 Subgroup assignment is not associated with
atopy status.
(DOC)
Table S42 Subgroup assignment is not associated with
fasting status.
(DOC)
Table S43 Subgroup assignment is not associated with
IgE titers.
(DOC)
Table S44 Subgroups assignment is not associated with
medical history of acid reflux.
(DOC)
Table S45 Association between BMI (at screening) and
subgroup assignment.
(DOC)
Table S46 Association between subgroup assignment
and days since quiet visit.
(DOC)
Text S1 Extensive details of the study are provided in
this 101 page document.
(DOC)
Acknowledgments
We gratefully acknowledge the patients who donated samples, the Asthma
Observational Study Teams at the clinical sites and at Wyeth (now Pfizer),
and Christine Hall for sample chain of custody verification.
Author Contributions
Conceived and designed the experiments: JLR CIC AJD SJG. Performed
the experiments: AAW HML CGS RCR DKE. Analyzed the data: STH
USB PSR AAH DKM FWI MO DGR. Wrote the paper: MO STH PSR
AAH FWI USB. Participated in study design, recruited patients, performed
study procedures: USB STH CMB PJT AJW PGB DIB LBI GLC GWB
GWB JWB. Recruited subjects, performed study procedures: PHH JES
RLM MK BHG. Medical Monitor: CMM.
References
1. Sykes A, Seemungal T (2008) Recent advances in exacerbations of asthma.
Thorax 63: 758–760.
2. Harrison TW, Oborne J, Newton S, Tattersfield AE (2004) Doubling the dose of
inhaled corticosteroid to prevent asthma exacerbations: randomised controlled
trial. Lancet 363: 271–275.
3. Rice-McDonald G, Bowler S, Staines G, Mitchell C (2005) Doubling daily
inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of
asthma in adults. Intern Med J 35: 693–698.
4. Belda J, Margarit G, Martinez C, Bellido-Casado J, Casan P, et al. (2007) Anti-
inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in
asthma exacerbations. Eur Respir J 30: 1143–1149.
5. Barnes PJ (2007) Scientific rationale for using a single inhaler for asthma control.
Eur Respir J 29: 587–595.
6. Boyce JA, Broide D,Matsumoto K, Bochner BS (2009) Advances in mechanisms of
asthma, allergy, and immunology in 2008. J Allergy Clin Immunol 123: 569–574.
7. Wenzel SE (2009) Eosinophils in asthma–closing the loop or opening the door?
N Engl J Med 360: 1026–1028.
8. Sykes A, Johnston SL (2008) Etiology of asthma exacerbations. J Allergy Clin
Immunol 122: 685–688.
9. Qiu Y, Zhu J, Bandi V, Guntupalli KK, Jeffery PK (2007) Bronchial mucosal
inflammation and upregulation of CXC chemoattractants and receptors in
severe exacerbations of asthma. Thorax 62: 475–482.
10. O’Toole M, Bjornsdottir U, Holgate ST, Reddy PS, Hill AA, et al. (2009)
Biological Mechanism Associated with Asthma Exacerbation Attack as Revealed
By Gene Expression Patterns of Peripheral Blood Mononuclear Cells. Journal of
Allergy and Clinical Immunology 123: S154.
11. Murphy S, Bleecher E, Bousey H, Buist A, Busse WW, et al. (1997) Guidelines
for the Diagnosis and Management of Asthma.
12. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J Roy Stat Soc. pp 289–300.
13. Hartigan JA, Wong MA (1979) A K-means clustering algorithm. Applied
Statistics 28: 100–108.
14. Rousseeuw PJ (1987) Silhouettes: A graphical aid to the interpretation and
validation of cluster analysis. J Comput Appl Math 20: 53–65.
15. McShane LM, Radmacher MD, Freidlin B, Yu R, Li MC, et al. (2002) Methods
for assessing reproducibility of clustering patterns observed in analyses of
microarray data. Bioinformatics 18: 1462–1469.
16. Baldi P, Long AD (2001) A Bayesian framework for the analysis of microarray
expression data: regularized t -test and statistical inferences of gene changes.
Bioinformatics 17: 509–519.
17. Mariani TJ, Budhraja V, Mecham BH, Gu CC, Watson MA, et al. (2003) A
variable fold change threshold determines significance for expression micro-
arrays. Faseb J 17: 321–323.
18. McCarthy DJ, Smyth GK (2009) Testing significance relative to a fold-change
threshold is a TREAT. Bioinformatics 25: 765–771.
19. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, et al. (2005)
Identification and functional significance of genes regulated by structurally
different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102:
3697–3702.
20. Whalen KA, Legault H, Hang C, Hill A, Kasaian M, et al. (2008) In vitro
allergen challenge of peripheral blood induces differential gene expression in
mononuclear cells of asthmatic patients: inhibition of cytosolic phospholipase
A2alpha overcomes the asthma-associated response. Clin Exp Allergy 38:
1590–1605.
21. Liu K, Catalfamo M, Li Y, Henkart PA, Weng NP (2002) IL-15 mimics T cell
receptor crosslinking in the induction of cellular proliferation, gene expression,
and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci U S A 99:
6192–6197.
22. Deng J, Dekruyff RH, Freeman GJ, Umetsu DT, Levy S (2002) Critical role of
CD81 in cognate T-B cell interactions leading to Th2 responses. Int Immunol
14: 513–523.
23. Kasprowicz DJ, Kohm AP, Berton MT, Chruscinski AJ, Sharpe A, et al. (2000)
Stimulation of the B cell receptor, CD86 (B7-2), and the beta 2-adrenergic
receptor intrinsically modulates the level of IgG1 and IgE produced per B cell.
J Immunol 165: 680–690.
24. Kasaian MT, Donaldson DD, Tchistiakova L, Marquette K, Tan XY, et al.
(2007) Efficacy of IL-13 neutralization in a sheep model of experimental asthma.
Am J Respir Cell Mol Biol 36: 368–376.
25. Wills-Karp M (2004) Interleukin-13 in asthma pathogenesis. Curr Allergy
Asthma Rep 4: 123–131.
26. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, et al. (1998)
Interleukin-13: central mediator of allergic asthma. Science 282: 2258–2261.
27. Wynn TA (2003) IL-13 effector functions. Annu Rev Immunol 21: 425–456.
28. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, et al. (2008) Cluster
analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178:
218–224.
29. Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, et al.
(2006) Respiratory syncytial virus induces TLR3 protein and protein kinase R,
leading to increased double-stranded RNA responsiveness in airway epithelial
cells. J Immunol 176: 1733–1740.
Asthma Exacerbation Pathways
PLoS ONE | www.plosone.org 18 July 2011 | Volume 6 | Issue 7 | e21902
30. Iwamura C, Nakayama T (2008) Toll-like receptors in the respiratory system:
their roles in inflammation. Curr Allergy Asthma Rep 8: 7–13.
31. Sears MR, Johnston NW (2007) Understanding the September asthma
epidemic. J Allergy Clin Immunol 120: 526–529.
32. Makela MJ, Halminen M, Ruuskanen O, Puhakka T, Pirhonen J, et al. (1999)
Lack of induction by rhinoviruses of systemic type I interferon production or
enhanced MxA protein expression during the common cold. Eur J Clin
Microbiol Infect Dis 18: 665–668.
33. Xatzipsalti M, Kyrana S, Tsolia M, Psarras S, Bossios A, et al. (2005) Rhinovirus
viremia in children with respiratory infections. Am J Respir Crit Care Med 172:
1037–1040.
34. Aoki T, Matsumoto Y, Hirata K, Ochiai K, Okada M, et al. (2009) Expression
profiling of genes related to asthma exacerbations. Clin Exp Allergy 39:
213–221.
35. Sutherland ER, Martin RJ (2007) Asthma and atypical bacterial infection. Chest
132: 1962–1966.
36. Wos M, Sanak M, Soja J, Olechnowicz H, Busse WW, et al. (2008) The presence
of rhinovirus in lower airways of patients with bronchial asthma. Am J Respir
Crit Care Med 177: 1082–1089.
37. Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde RS, et al. (2009)
Allergenicity resulting from functional mimicry of a Toll-like receptor complex
protein. Nature 457: 585–588.
38. Becker S, Dailey L, Soukup JM, Silbajoris R, Devlin RB (2005) TLR-2 is
involved in airway epithelial cell response to air pollution particles. Toxicol Appl
Pharmacol 203: 45–52.
39. Williams AS, Leung SY, Nath P, Khorasani NM, Bhavsar P, et al. (2007) Role of
TLR2, TLR4, and MyD88 in murine ozone-induced airway hyperresponsive-
ness and neutrophilia. J Appl Physiol 103: 1189–1195.
40. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, et al. (2002) Novel signal
transduction pathway utilized by extracellular HSP70: role of toll-like receptor
(TLR) 2 and TLR4. J Biol Chem 277: 15028–15034.
41. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, et al. (2002)
Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.
Science 298: 1025–1029.
42. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, et al. (2001) The
extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276:
10229–10233.
43. Saemann MD, Weichhart T, Zeyda M, Staffler G, Schunn M, et al. (2005)
Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive
immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest 115:
468–475.
44. Smiley ST, King JA, Hancock WW (2001) Fibrinogen stimulates macrophage
chemokine secretion through toll-like receptor 4. J Immunol 167: 2887–2894.
45. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, et al. (2002)
Cutting edge: the immunostimulatory activity of the lung surfactant protein-A
involves Toll-like receptor 4. J Immunol 168: 5989–5992.
46. Burgel PR, Nadel JA (2008) Epidermal growth factor receptor-mediated innate
immune responses and their roles in airway diseases. Eur Respir J 32:
1068–1081.
47. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, et al. (2009)
House dust mite allergen induces asthma via Toll-like receptor 4 triggering of
airway structural cells. Nat Med 15: 410–416.
48. Le Souef PN (2009) Gene-environmental interaction in the development of
atopic asthma: new developments. Curr Opin Allergy Clin Immunol 9:
123–127.
49. Reed CE, Milton DK (2001) Endotoxin-stimulated innate immunity: A
contributing factor for asthma. J Allergy Clin Immunol 108: 157–166.
50. Simpson JL, Brooks C, Douwes J (2008) Innate immunity in asthma. Paediatr
Respir Rev 9: 263–270.
51. Tamari M, Harada M, Hirota T, Nakamura Y (2009) Host molecular defense
mechanisms against Chlamydophila pneumoniae and genetic studies of
immune-response-related genes in asthma. Recent Pat Inflamm Allergy Drug
Discov 3: 17–25.
52. Eder W, Klimecki W, Yu L, von Mutius E, Riedler J, et al. (2004) Toll-like
receptor 2 as a major gene for asthma in children of European farmers. J Allergy
Clin Immunol 113: 482–488.
53. Fageras Bottcher M, Hmani-Aifa M, Lindstrom A, Jenmalm MC, Mai XM,
et al. (2004) A TLR4 polymorphism is associated with asthma and reduced
lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children.
J Allergy Clin Immunol 114: 561–567.
54. Lazarus R, Raby BA, Lange C, Silverman EK, Kwiatkowski DJ, et al. (2004)
TOLL-like receptor 10 genetic variation is associated with asthma in two
independent samples. Am J Respir Crit Care Med 170: 594–600.
55. Smit LA, Siroux V, Bouzigon E, Oryszczyn MP, Lathrop M, et al. (2009) CD14
and toll-like receptor gene polymorphisms, country living, and asthma in adults.
Am J Respir Crit Care Med 179: 363–368.
56. Yang IA, Fong KM, Holgate ST, Holloway JW (2006) The role of Toll-like
receptors and related receptors of the innate immune system in asthma. Curr
Opin Allergy Clin Immunol 6: 23–28.
57. Koppelman GH, Reijmerink NE, Colin Stine O, Howard TD, Whittaker PA,
et al. (2001) Association of a promoter polymorphism of the CD14 gene and
atopy. Am J Respir Crit Care Med 163: 965–969.
58. Nakao F, Ihara K, Kusuhara K, Sasaki Y, Kinukawa N, et al. (2001) Association
of IFN-gamma and IFN regulatory factor 1 polymorphisms with childhood
atopic asthma. J Allergy Clin Immunol 107: 499–504.
59. Sharma M, Batra J, Mabalirajan U, Goswami S, Ganguly D, et al. (2004)
Suggestive evidence of association of C-159T functional polymorphism of the
CD14 gene with atopic asthma in northern and northwestern Indian
populations. Immunogenetics 56: 544–547.
60. Wang TN, Chu YT, Chen WY, Feng WW, Shih NH, et al. (2006) Association of
interferon-gamma and interferon regulatory factor 1 polymorphisms with
asthma in a family-based association study in Taiwan. Clin Exp Allergy 36:
1147–1152.
61. Woo JG, Assa’ad A, Heizer AB, Bernstein JA, Hershey GK (2003) The -159
CRT polymorphism of CD14 is associated with nonatopic asthma and food
allergy. J Allergy Clin Immunol 112: 438–444.
62. Boyman O, Purton JF, Surh CD, Sprent J (2007) Cytokines and T-cell
homeostasis. Curr Opin Immunol 19: 320–326.
63. Ohteki T, Yoshida H, Matsuyama T, Duncan GS, Mak TW, et al. (1998) The
transcription factor interferon regulatory factor 1 (IRF-1) is important during the
maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1+ T) cells,
natural killer cells, and intestinal intraepithelial T cells. J Exp Med 187:
967–972.
64. Zhang X, Sun S, Hwang I, Tough DF, Sprent J (1998) Potent and selective
stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8:
591–599.
65. Bierbaum S, Nickel R, Zitnik S, Ahlert I, Lau S, et al. (2006) Confirmation of
association of IL-15 with pediatric asthma and comparison of different controls.
Allergy 61: 576–580.
66. Kurz T, Strauch K, Dietrich H, Braun S, Hierl S, et al. (2004) Multilocus
haplotype analyses reveal association between 5 novel IL-15 polymorphisms and
asthma. J Allergy Clin Immunol 113: 896–901.
67. Janeway CA, Jr., Medzhitov R (2002) Innate immune recognition. Annu Rev
Immunol 20: 197–216.
Asthma Exacerbation Pathways
PLoS ONE | www.plosone.org 19 July 2011 | Volume 6 | Issue 7 | e21902
